<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265040</url>
  </required_header>
  <id_info>
    <org_study_id>TORCH-Plus DZHK21</org_study_id>
    <nct_id>NCT04265040</nct_id>
  </id_info>
  <brief_title>TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies</brief_title>
  <acronym>TORCH-Plus</acronym>
  <official_title>TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique
      resource of clinical data and high quality biological samples to enable innovative clinical
      and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy
      registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients
      were recruited as planned. Taken together, patient data showed that the prevalence of these
      diseases is much higher in men than in women, atrial fibrillation is common in all forms of
      CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.

      This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The
      second phase DZHK TORCH-Plus consists of 4 main modules: 1. &quot;Clinical phenotyping, follow-up
      &amp; biosampling&quot; 2. &quot;Genomics&quot;, 3. &quot;Inflammation&quot; and 4. &quot;Biomarker&quot;. The central aims are 1)
      to significantly increase the number of probands (n = 4340) in order to better address the
      different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or
      with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the
      longitudinal with a further follow-up to achieve sufficient events and thereby derive
      clinical recommendations for risk assessment, 3) to increase the number of probands with
      state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis,
      gender and to determine or predict genotypes based for outcome, 5) to validate novel
      biomarkers developed in other DZHK studies, and 6) to foster active cooperation with
      international CMP registries and partners from industry.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2040</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <condition>DCM - Dilated Cardiomyopathy</condition>
  <condition>HCM - Hypertrophic Cardiomyopathy</condition>
  <condition>HOCM - Hypertrophic Obstructive Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <condition>Left Ventricular Noncompaction Cardiomyopathy</condition>
  <condition>Amyloidosis</condition>
  <condition>Inflammatory Cardiomyopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-ischemic structural cardiomyopathies

          -  Age ≥ 18 or ≤ 80 years

          -  The patient is able to understand the declaration of consent and to sign it dated

          -  At least one of the following diagnoses depending on the specific TORCH-

        Plus inclusion / exclusion - SOP:

        Dilated Cardiomyopathy (DCM)

          -  family / genetic

          -  inflammatory / persistent myocarditis

          -  idiopathic (after exclusion secondary cause)

          -  left sided systolic dysfunction (EF ≤ 45%)

        Left ventricular hypertrophy

          -  sarcomere hypertrophic cardiomoypathia (HCM, HOCM)

          -  amyloid (AL: light chains, TTR: transthyretin, wild type)

        Left ventricular non-compaction cardiomyopathy (LVNC)

        Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)

        Exclusion Criteria:

        The following exclusion criteria have been defined and must be taken from the TORCH-Plus
        specific inclusion / exclusion - SOP in detail:

          -  Age: &lt;18 years or&gt; 80 years

          -  Patient has other (cardiac) previous illnesses:

               -  uncontrollable arterial hypertension

               -  primary pulmonary arterial hypertension

               -  radiation therapy in the chest area

               -  addiction (drug or alcohol abuse)

               -  life expectancy &lt;1 year due to non-cardiological pre-existing conditions

               -  significant heart valve disease

               -  ischemic diseases and severe congenital heart diseases (including VSD, Fallot
                  tetralogy, Ebstein anomaly)

               -  chemotoxic cardiomyopathy

               -  condition after myocarditis

               -  combination of several traditional risk factors (e.g. hypertension and diabetes
                  mellitus)

               -  advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)

               -  Tachymyopathie
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Benjamin Meder</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathies, registry, data, biomaterial, genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

